CPSE:NOVO BPharmaceuticals
Novo Nordisk Turns Hims Lawsuit Into Telehealth Weight Loss Channel
Novo Nordisk (CPSE:NOVO B) has resolved its legal dispute with Hims & Hers Health over compounded GLP-1 weight loss treatments.
The two companies have entered a new commercial partnership for Hims & Hers to distribute Novo Nordisk's branded weight loss drugs, including Ozempic and Wegovy, via its telehealth platform.
As part of the agreement, Hims & Hers will stop promoting compounded GLP-1 products, focusing instead on Novo Nordisk's FDA approved therapies.
Novo Nordisk, known for its...